Skip to main content
. 2019 Oct 11;9(4):428–436. doi: 10.1093/jpids/piz064

Table 1.

Patient, Admission, and Febrile Neutropenia (FN) Episode Characteristicsa

Characteristic n (%) or Median (Q1, Q3)
Pre-Intervention Post-Intervention
(2009–2011) (2013–2015) P Valueb
Patients n = 285 n = 309
 Age at study entry (years) 6.2 (3.1, 12.1) 6.4 (3.2, 12.3) .93
 Female gender 135 (47) 133 (43) .29
 Race .59
  White 204 (72) 216 (70)
  Black/African American 17 (6) 12 (4)
  Asian 14 (5) 22 (7)
  Other 7 (2) 9 (3)
  Unknown 43 (15) 50 (16)
 Ethnicity .13
  Hispanic/Latino 33 (12) 29 (9)
  Not Hispanic/Latino 203 (71) 242 (78)
  Unknown 49 (17) 38 (12)
 Underlying oncologic diagnosis .06
  Acute lymphoblastic leukemia 112 (39) 115 (37)
  Acute myelogenous leukemia 14 (5) 26 (8)
  Hodgkin lymphoma 9 (3) 8 (3)
  Non-Hodgkin lymphoma 15 (5) 17 (6)
  Acute promyelocytic leukemia 8 (3) 0 (0)
  Otherc 3 (1) 2 (1)
  Solid tumor 124 (44) 141 (46) .18
   Central nervous system tumors 33 (27) 31 (22)
   Neuroblastoma 24 (20) 31 (22)
   Wilms renal tumor 8 (7) 6 (4)
   Osteosarcoma 16 (13) 19 (14)
   Ewing sarcoma 4 (3) 16 (12)
   Other 39 (31) 38 (27)
 Admissions per patient 4 (2, 7) 4 (2, 6) .16
 Admissions with any FN episodes per patient 2 (1, 3) 2 (1, 3) .30
 FN episodes per patient 2 (1, 3) 2 (1, 3) .42
Admissions n = 1410 n = 1356
 Total patient days 13 447 14 440
 Total central-line days (oncology units) 30 982 36 439
 Length of stay (days) across all admissions 4 (2, 8) 4 (2, 8) .63
 FN episode during admission 657 (47) 649 (48) .51
 Length of stay (days) during admission with FN 7 (4, 20) 6 (3, 17) .02
FN episodes n = 697 n = 691
 Total FN days 6226 6273
 Episode length (days) 6 (4, 9) 5 (4, 9) .20
 Admitting location .71
  Oncology floor 645 (93) 643 (93)
  Intensive care unit or Step-down unit 52 (7) 48 (7)

Nineteen patients had FN episodes in both the pre- and post-intervention periods.

Abbreviation: FN, febrile neutropenia.

aN = 575 uniqe patients, 2766 admissions, 1388 FN episodes. Nineteen patients had FN episodes in both the pre- and post-intervention periods.

b P value from the χ2 test for categorical variables testing for difference in distribution by period; P value from the Wilcoxon rank sum test for continuous variables testing for difference in distribution by period.

cOther includes pre: 1 chronic myeloid leukemia (CML), 1 intermediate/gray zone lymphoma, 1 post-transplant lymphoproliferative disorders (PTLD); and post: 1 CML, 1 PTLD.